Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 1

Optimal timing for antihypertensive dosing: focus on valsartan

Authors Ramón C Hermida, Diana E Ayala, Carlos Calvo

Published 15 March 2007 Volume 2007:3(1) Pages 119—131

Ramón C Hermida1, Diana E Ayala1, Carlos Calvo2

1Bioengineering & Chronobiology Laboratories, University of Vigo, Campus Universitario, Vigo, 36200 Spain; 2Hypertension and Vascular Risk Unit, Hospital Clinico Universitario, Santiago de Compostela, 15706 Spain

Abstract: Some specific features of the 24 h blood pressure (BP) pattern are linked to the progressive injury of target tissues and the triggering of cardiac and cerebrovascular events. In particular, many studies show the extent of the nocturnal BP decline relative to the diurnal BP mean (the diurnal/nocturnal ratio, an index of BP dipping) is deterministic of cardiovascular injury and risk. Normalization of the circadian BP pattern is considered to be an important clinical goal of pharmacotherapy because it may slow the advance of renal injury and avert end-stage renal failure. The chronotherapy of hypertension takes into account the epidemiology of the BP pattern, plus potential administration-time determinants of the pharmacokinetics and dynamics of antihypertensive medications, as a means of enhancing beneficial outcomes and/or attenuating or averting adverse effects. Thus, bedtime dosing with nifedipine gastrointestinal therapeutic system (GITS) is more effective than morning dosing, while also reducing significantly secondary effects. The dose-response curve, therapeutic coverage, and efficacy of doxazosin GITS are all markedly dependent on the circadian time of drug administration. Moreover, valsartan administration at bedtime as opposed to upon wakening results in improved diurnal/nocturnal ratio, a significant increase in the percentage of patients with controlled BP after treatment, and significant reductions in urinary albumin excretion and plasma fibrinogen. Chronotherapy provides a means of individualizing treatment of hypertension according to the circadian BP profile of each patient, and constitutes a new option to optimize BP control and reduce risk.

Keywords: valsartan, ambulatory blood pressure monitoring, dipper, nondipper, hypertension, chronotherapy, circadian rhythm

Download Article [PDF] 

Readers of this article also read:

Bevacizumab for glioblastoma

Narita Y

Therapeutics and Clinical Risk Management 2015, 11:1759-1765

Published Date: 1 December 2015

Diagnosis and management of xerostomia and hyposalivation

Villa A, Connell CL, Abati S

Therapeutics and Clinical Risk Management 2015, 11:45-51

Published Date: 22 December 2014

New treatments for genotype 1 chronic hepatitis C – focus on simeprevir

Kanda T, Nakamoto S, Wu S, Yokosuka O

Therapeutics and Clinical Risk Management 2014, 10:387-394

Published Date: 24 May 2014

Adjuvant corneal crosslinking to prevent hyperopic LASIK regression

Aslanides IM, Mukherjee AN

Clinical Ophthalmology 2013, 7:637-641

Published Date: 31 March 2013

Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles

Wang W, Zhu R, Xie Q, Li A, Xiao Y, Liu H, Cui D, Chen Y, Wang S

International Journal of Nanomedicine 2012, 7:3667-3677

Published Date: 17 July 2012

The role of somatostatin in 67 consecutive pancreatectomies: a randomized clinical trial

Anastasios Katsourakis, Louiza Oikonomou, Efthimios Chatzitheoklitos, et al

Clinical and Experimental Gastroenterology 2010, 3:179-183

Published Date: 7 December 2010